Arrowhead Aims for HBV IND in Early 2013, Releases Preclinical Data from Program | GenomeWeb

Just months after adding a hepatitis B treatment to its pipeline, Arrowhead Research's top official this week said that the company expects the program to yield an investigational new drug application in the first half of next year.

Arrowhead, which just released its fiscal second-quarter financial results, also announced preclinical data showing that siRNAs formulated in the company's proprietary dynamic polyconjugate, or DPC, technology could significantly reduce levels of the viral RNA and DNA in animal models of the disease.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Genome Research this week: Platinum variant catalog, algorithmic strategy for upgrading fragmented assemblies, and more.

Sequencing of a 10,000-year-old mummy leads to its repatriation to the Fallon Paiute-Shoshone Tribe, Nature News reports.

The final text of the bill to reauthorize the America COMPETES Act might smooth over the differences between NSF and the House science committee, ScienceInsider says.

Four Republican lawmakers urge President-elect Donald Trump to keep Francis Collins as NIH director, Stat News reports.